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hypoglycemia were €0, €189 and €695 per event separately. CONCLUSIONS: Hypo-
glycemia is common acute side effect in treatment of T2DM patients, which asso-
ciated with considerable health and economic burden to patients and their family.
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OBJECTIVES: Although the prevalence of type 2 diabetes (T2D) is dramatically in-
creasing worldwide, data on the prevalence, prevalence of those at risk, and the
burden of these patients in Russia is lacking. METHODS: The data source for the
current study was the 2011 Russia National Health and Wellness Survey (NHWS), a
cross-sectional patient-reported health survey of adults in Russia (N10,039). Re-
spondents who reported a diagnosis of T2D were compared with non-T2D controls
on health status (measured using the SF-12v2), work productivity (measured using
the WPAI questionnaire), and number of resource use events using regression
modeling controlling for sociodemographic and health history variables. Among
respondents without a diagnosis of T2D, the prevalence and burden of key risk
factors were reported. RESULTS: A total of 288 respondents in Russia reported a
diagnosis of T2D (weighted prevalence: 2.77%). Among those not reporting a diag-
nosis, several risk factors were highly prevalent: 49.6% were overweight/obese,
17.5% had a family history of T2D, 34.5% currently smoke, 46.7% do not regularly
exercise, and 20.2% have hypertension. Patients with T2D were older (57.9 vs. 44.3),
had a lower annual income (19.1% vs. 11.2% had12,000 RUR), were more likely to
be obese (44.8% vs. 16.5%), and had a greater comorbidity burden (1.9 vs. 0.4) (all
p.05). Adjusting for group differences, patients with T2D reported significantly
worse physical health status (physical component summary scores: 43.46 vs. 46.25,
p.05). No significant differences were observed on work productivity or health
care resource use. CONCLUSIONS: The prevalence of T2D in Russia is modest but
may represent a large undiagnosed population, especially because the non-T2D
population reported a significant number of risk factors. The burden of T2D was
primarily observed through health status. Together, these results underscore the
importance of proper prevention and treatment of T2D.
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OBJECTIVES: Patients with acromegaly have significantly impaired health-related
quality of life (HRQOL). Results from a randomized, phase 3 study demonstrate
superior biochemical control for pasireotide LAR, a novel multireceptor somatosta-
tin analog, compared with octreotide LAR. The study also assessed patient-re-
ported HRQOL. METHODS: Medically naïve (after pituitary surgery or de novo)
patients with active acromegaly (GH level 5 g/L; elevated IGF-1) were random-
ized to receive pasireotide LAR 40mg (n176) or octreotide LAR 20mg (n182) in-
jections once every 28 days for 12 months. Biochemical control was defined as
GH2.5 g/L and normal IGF-1 at month 12. The AcroQoL questionnaire was used
to assess HRQOL. A change in AcroQoL total score of 9.8 was considered mean-
ingful based on a distribution-based estimate (1/2 standard deviation at baseline).
This analysis was conducted on patients with baseline and month 12 data (N275).
RESULTS: HRQoL improved from baseline to month 12 with both pasireotide LAR
(n132; mean [SD]  7.1 [14.7]) and octreotide LAR (n143; 5.1 [15.6]). Mean scores
were 58.5 and 55.9, respectively, at baseline and 65.3 and 61.5, respectively, at
month 12 for pasireotide LAR and octreotide LAR. These scores are consistent with
those previously reported for patients before and after effective treatment (56 [20];
65 [18]).1 Overall, 38.6% of pasireotide LAR patients met the AcroQoL criteria for a
clinically meaningful change vs. 34.3% of octreotide LAR patients. This pattern was
consistent for the AcroQoL physical and psychological subscales. For both treat-
ments at baseline and month 12, HRQOL was better in patients who achieved
biochemical control at month 12 (baseline: 62.9 [18.9] vs. 55.1 [19.5]); month 12: 66.9
[19.6] vs. 61.9 [22.0]). CONCLUSIONS: Pasireotide LAR treatment decreases GH and
IGF-1 and improves HRQOL. 1Webb et al, 2007.
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OBJECTIVES: To quantify patient preferences for outcomes associated with oral
type 2 diabetes mellitus (T2DM) treatments. METHODS: Adults in Sweden and
Germany with a self-reported physician diagnosis of T2DM and currently receiving
on oral anti-diabetic completed a web-enabled choice-format conjoint survey con-
sisting of a series of 9 choices between pairs of hypothetical medication profiles.
Each profile had different attributes within a pre-defined range, i.e., blood glucose
control (A1c), number of monthly mild-to-moderate hypoglycemic events (hypos) ,
one severe hypo per year (yes or no), weight gain per year, number of pills and
frequency of administration, and monthly cost to the patient. Choice questions
were based on an experimental design with known statistical properties. The sur-
vey was pretested with 25 patients using open-ended interviews. Bivariate probit
analysis was used to estimate probabilities for choosing how to take the medica-
tion based on patient characteristics and, conditional on that choice, preferences
for treatment outcomes. RESULTS:A total of 188 respondents in Sweden and 195 in
Germany completed the survey. Regarding the relative importance of the attributes
over the ranges included in both countries, weight gain was the most important
outcome followed by blood glucose control, for a once daily treatment. However,
avoiding a 5-kg weight gain was 1.5 times more important in Sweden and 2.3 times
more important in Germany than achieving moderate blood-glucose control. This
implies that blood glucose control was relatively more important to Swedish pa-
tients than German patients. Avoiding one severe hypo per year was the third most
important outcome in Sweden and fourth in Germany. In terms of the least impor-
tant outcome, it was number of pills taken once a day in Sweden and number of
monthly mild-to-moderate hypos in Germany. CONCLUSIONS: An oral T2DM
treatment that has no associated weight gain would be most preferred in both
Sweden and Germany.
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OBJECTIVES: An update of health economics analysis of type 2 diabetes mellitus
(T2DM) in adult population in Turkey was performed. The objectives of the analysis
were to determine the direct cost components caused by T2DM and its complica-
tions and also the loss of work productivity in T2DM. In this presentation, data on
work productivity are reported. METHODS: Forty centres were selected from the
list of centres in which adult T2DM patients were followed on a routine basis. These
centres were representative of the country, since they were selected by two-stage
cluster sampling. Data on work productivity were collected via “Work Productivity
and Activity Impairment Questionnaire: General Health V2.0 (WPAI:GH)”.
RESULTS: A total of 657 patients’ data were included in the analysis. The percent-
age of patients, who had a job, at the time of the study conducted, was 14.0%. This
figure was lower in patients with ophthalmic complications (8.7% vs. 15.9%;
p0.020) and with cardiovascular complications (4.1% vs. 15.7%; p0.002). Mean
scores of absenteeism, presenteeism and overall work productivity loss were
23.537.6%, 15.218.8%, and 38.637.8%, respectively. Overall impairment score of
work productivity was 22.725.0%. Patients with metabolic complications and
ophthalmic complications had reported more impairment (though non-signifi-
cant) (for metabolic complications 32.4% vs. 19.4%; p0.11; for ophthalmic compli-
cations 30.9% vs. 21.1%; p0.10). Overall impairment score of daily activities was
31.329.2%. Patients with metabolic complications and cardiovascular complica-
tions had reported more impairment (for metabolic complications 43.1% vs. 26.3%;
p0.001; and for cardiovascular complications 37.7% vs. 30.2%; p0.035).
CONCLUSIONS: DM is a disease that significantly impairs the opportunity to have
a job, and also impairs the work productivity and daily activities of patients. This
impairment is correlated with the presence of systemic complications. Thus, pre-
vention or effective treatment of complications in DM is crucial to improve the
social and economic consequences of the disease.
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OBJECTIVES: Cardiovascular disease is the major cause of death in patients with
type 2 diabetes (T2DM) and long-term follow-up from UKPDS showed improved
glycaemic control was associated with risk reduction for both myocardial infarc-
tion and death. The objective of this study was to quantify the expected difference
in long-term outcomes associated with blood glucose treated to target compared
with levels observed in clinical practice. METHODS: Data from UK primary care
(THIN) were used to obtain the demographic and risk factor profiles of patients
initiating monotherapy, dual therapy, and insulin-based therapy between 2005 and
2009. The Cardiff Type 2 Diabetes Model was initiated with cohort profiles consis-
tent with those subjects initiating monotherapy, and HbA1c change over time was
implemented under three scenarios: (1) HbA1c maintained at 6.5%; (2) therapy
escalation occurring at a threshold of 7.5%, and (3) therapy escalation occurring at
mean HbA1c levels observed in clinical practice. A 40-year time horizon using was
used with UK £ 2011 costs; both costs and benefits were discounted at 3.5%.
RESULTS:Data were available for 35,330 subjects; mean HbA1c (change) at therapy
initiation for mono, dual, and insulin therapy was 8.0% (-0.93%, p0.001), 8.5%
(-1.1%, p0.001), and 9.8% (-1.47%, p0.001), respectively. Under scenario 1, total
predicted costs (TC), life expectancy (LE), and quality-adjusted life-years (QALYs)
were £7,200, 16.4 years, and 13.7 QALYs, respectively. For scenario 2, TC, LE, and
QALYs were £14,416, 15.9 years, and 13.2 QALYs, respectively, whereas for scenario
3, TC increased to £14,914, while LE and QALYs decreased to 15.6 years and 12.8
QALYs, respectively. CONCLUSIONS: Failure to achieve glycaemic goals results in de-
creased life and quality adjusted life expectancy and excessive health care costs. Given
current budgetary constraints, an ageing population, and increasing obesity, it is impera-
tive that patients with T2DM are optimally managed in routine clinical practice.
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